Angers

• A phase III placebo-controlled efficacy and safety study of mocravimod as an adjunctive and maintenance treatment in AML patients undergoing … Recruiting
  2024-512752-38-00 5 2025-09-09 Adjunctive and maintenance treatment to HCT
• ENGIC 01 - COLOSOTO: A single-arm phase II study evaluating 5-fluorouracil plus Panitumumab (anti-EGFR) and Sotorasib (KRAS G12C inhibitor) … Recruiting
  2024-514030-20-00 4 2025-08-29 colorectal cancer
• PLATFORM - A PLATFORM TRIAL, EVALUATING NEW DRUGS OR COMBINATION IN RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMAS Recruiting
  2024-514954-63-00 9 2025-08-20 RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMAS
• Testing ivonescimab versus FOLFOX in advanced biliary tract cancer patients Recruiting
  2024-515875-36-00 4 2025-08-18 Advanced biliary tract cancer (BTC)
• A clinical study of ifinatamab deruxtecan to treat metastatic prostate cancer (MK 2400 01A) Recruiting
  2024-516036-94-00 9 2025-08-12 Metastatic castrate resistant prostate cancer - mCRPC
• A Phase 1/2, open-label, multicenter, dose-escalation, and dose‑optimization study to evaluate the safety, tolerability, and activity of EIK … Recruiting
  2024-520395-99-00 7 2025-08-12 Advanced solid tumors
• A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia Recruiting
  2024-520154-38-00 5 2025-07-29 Acute Myeloid Luekemia
• Personalizing the use of pembrolizumab for patients who have a strong response in early triple negative breast cancer Recruiting
  2024-515787-31-00 5 2025-07-18 Patient with early triple-negative breast cancer (TNBC) achieving path
• Study of Sacituzumab Govitecan Versus Standard of Care in Participants with Previously Treated Extensive Stage Small Cell Lung Cancer Recruiting
  2024-515884-69-00 5 2025-07-16 Extensive Stage Small Cell Lung Cancer (ES-SCLC)
• A Study to Assess safety and Effectiveness of the Inavolisib Plus a CDK4/6 Inhibitor and Letrozole Versus Placebo Plus a CDK4/6 Inhibitor an … Recruiting
  2024-516162-11-00 5 2025-07-14 Endocrine-Sensitive phosphatidylinositol 3-kinase (PIK3CA)-Mutated, Ho
• A phase 3, open-label, controlled, randomized study of newly diagnosed multiple myeloma treatment, designed to evaluate the efficacy and saf … Recruiting
  2024-516418-39-00 5 2025-07-09 Multiple Myeloma
• Prevention of secondary infections by interferon gamma in ICU-acquired sustained immune-suppression: a randomized trial Recruiting
  2024-516780-93-00 5 2025-07-09 Sustained immunosuppression
• A study to evaluate the efficacy of APG-2575 (Lisaftoclax) plus azacitidine (AZA) vs. placebo plus AZA in newly diagnosed adult subjects wit … Recruiting
  2024-517247-31-00 5 2025-07-07 Newly Diagnosed Higher Risk Myelodysplastic Syndrome
• An Open-Label Extension Study of Subjects who Received an Avalyn Inhaled Antifibrotic Agent Recruiting
  2024-518289-28-00 4 2025-07-04 Progressive pulmonary fibrosis [PPF] Idiopathic pulmonary fibrosis [I
• Efficacy of methylprednisolone pulses in neuroendocrine cells hyperplasia of infancy: an early phase study (CORTICONEHI). Recruiting
  2023-508132-65-00 4 2025-06-30 NEUROENDOCRINE CELLS HYPERPLASIA OF INFANCY
• IFM2024-06 : A multi-center, open-label, phase 2 randomized study of elranatamab plus lenalidomide versus daratumumab plus lenalidomide as p … Recruiting
  2024-517325-43-00 4 2025-06-19 multiple myeloma
• Safety, efficacy, and pharmacokinetics of BNT327 in combination with chemotherapy and other investigational agents for lung cancer Recruiting
  2024-515764-31-00 10 2025-06-13 Non-small cell lung cancer
• Systemic antitumor treatment with or without pressurized intraperitoneal aerosol chemotherapy (PIPAC) for colon peritoneal metastases – a mu … Recruiting
  2024-514560-10-00 4 2025-06-12 Patients with newly diagnosed advanced peritoneal metastasis from colo
• Study of Adagrasib plus Pembrolizumab plus Chemotherapy vs. Placebo plus Pembrolizumab plus Chemotherapy in Participants with Previously Unt … Recruiting
  2024-515698-85-00 5 2025-06-12 Locally Advanced or Metastatic Non-small Cell Lung Cancer
• Blocage de l'interféron-ɣ par le ruxolitinib pour le traitement de la myosite à inclusion : un essai de phase IIb Recruiting
  2023-507666-32-00 4 2025-05-27 Inclusion body Myositis
• EORTC-2238-GUCG: Improving impact of anti-androgen treatments on patient's daily life and their cancer Recruiting
  2023-506817-23-01 5 2025-05-23 Metastatic hormone naïve prostate cancer (mHNPC)
• Cabozantinib and Nivolumab among older patients with renal-cell carcinoma, a prospective cohort with geriatric, pharmacologic and patient-re … Recruiting
  2024-516650-22-00 6 2025-05-16 Renal carcinoma
• A study to evaluate the benefit of adding durvalumab after chemotherapy, durvalumab and surgery in patients with early-stage, operable, non- … Recruiting
  2023-508773-82-00 5 2025-05-06 Stage IIB-IIIB (N2) resectable non small cell lung cancer
• MODULO Recruiting
  2024-515793-27-01 5 2025-04-30 HIV

Showing 169–192 of 611 trials